Compass Therapeutics (NASDAQ:CMPX) Given New $4.00 Price Target at Citizens Jmp

Compass Therapeutics (NASDAQ:CMPX) had its target price dropped by equities research analysts at Citizens Jmp to $4.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s target price would suggest a potential upside of 222.58% from the company’s current price.

Other equities analysts have also issued research reports about the company. Stifel Nicolaus set a $6.00 price target on Compass Therapeutics in a report on Monday, June 1st. Guggenheim dropped their target price on Compass Therapeutics to $4.00 and set a “buy” rating on the stock in a report on Wednesday. LADENBURG THALM/SH SH initiated coverage on Compass Therapeutics in a report on Wednesday, July 1st. They set a “buy” rating and a $5.00 price target for the company. Citigroup restated a “market outperform” rating on shares of Compass Therapeutics in a research report on Wednesday. Finally, Wall Street Zen downgraded shares of Compass Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.21.

Compass Therapeutics Price Performance

Shares of NASDAQ CMPX opened at $1.24 on Wednesday. The business has a 50-day moving average of $2.14 and a two-hundred day moving average of $2.96. The company has a market capitalization of $223.31 million, a price-to-earnings ratio of -3.10 and a beta of 0.95. Compass Therapeutics has a 1 year low of $1.15 and a 1 year high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, equities research analysts expect that Compass Therapeutics will post -0.47 earnings per share for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors have recently made changes to their positions in the stock. Welch & Forbes LLC grew its stake in Compass Therapeutics by 26.7% during the 4th quarter. Welch & Forbes LLC now owns 19,000 shares of the company’s stock valued at $102,000 after acquiring an additional 4,000 shares in the last quarter. Parallel Advisors LLC acquired a new position in shares of Compass Therapeutics in the 1st quarter valued at about $28,000. ProShare Advisors LLC lifted its position in shares of Compass Therapeutics by 41.0% in the fourth quarter. ProShare Advisors LLC now owns 23,972 shares of the company’s stock worth $129,000 after purchasing an additional 6,968 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Compass Therapeutics by 2,572.6% in the first quarter. PNC Financial Services Group Inc. now owns 11,038 shares of the company’s stock worth $58,000 after purchasing an additional 10,625 shares in the last quarter. Finally, HB Wealth Management LLC acquired a new stake in shares of Compass Therapeutics during the second quarter worth approximately $29,000. 68.43% of the stock is owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company’s research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.